The amyloid-β(1–42)-oligomer interacting peptide D-AIP possesses favorable biostability, pharmacokinetics, and brain region distribution

We have previously developed a unique 8-amino acid Aβ42 oligomer-Interacting Peptide (AIP) as a novel anti-amyloid strategy for the treatment of Alzheimer’s disease. Our lead candidate has successfully progressed from test tubes (i.e., in vitro characterization of protease-resistant D-AIP) to transg...

Descripción completa

Detalles Bibliográficos
Autores principales: Shobo, Adeola, James, Nicholas, Dai, Daniel, Röntgen, Alexander, Black, Corbin, Kwizera, Jean-Robert, Hancock, Mark A., Huy Bui, Khanh, Multhaup, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752909/
https://www.ncbi.nlm.nih.gov/pubmed/34896396
http://dx.doi.org/10.1016/j.jbc.2021.101483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752909/
https://www.ncbi.nlm.nih.gov/pubmed/34896396
http://dx.doi.org/10.1016/j.jbc.2021.101483

Ejemplares similares